Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial. (Q53256103)

From Wikidata

Jump to navigation Jump to search

scientific article published in June 2006

edit

Language	Label	Description	Also known as
English	Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial.	scientific article published in June 2006

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

title

Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

main subject

(S)-etiracetam

1 reference

based on heuristic

inferred from title

author

Paul-André Despland

series ordinal

5

object named as

Despland PA

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

author name string

Genton P

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

Sadzot B

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

Fejerman N

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

Peltola J

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

Steinhoff B

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

Rektor I

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

Wroe S

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

Maubrey MC

series ordinal

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

Vandervelden C

series ordinal

10

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

van Hammée G

series ordinal

11

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

Schlit AF

series ordinal

12

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

van Paesschen W

series ordinal

13

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

language of work or name

English

0 references

publication date

1 June 2006

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

published in

Acta Neurologica Scandinavica

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

volume

113

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

issue

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

page(s)

387-394

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

cites work

Revisiting the concept of identifiable neurons

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00647.X

retrieved

21 January 2018

A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00647.X

retrieved

21 January 2018

Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00647.X

retrieved

21 January 2018

An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00647.X

retrieved

21 January 2018

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00647.X

retrieved

21 January 2018

The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00647.X

retrieved

21 January 2018

Long-term continuation of levetiracetam in patients with refractory epilepsy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00647.X

retrieved

21 January 2018

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00647.X

retrieved

21 January 2018

Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00647.X

retrieved

21 January 2018

Identifiers

DOI

10.1111/J.1600-0404.2006.00647.X

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

PubMed publication ID

16674605

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16674605

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/16674605

ResearchGate publication ID

7105555

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53256103&oldid=2175882885"